available at www.sciencedirect.com
journal homepage: www.europeanurology.com

European Association of Urology

Prostate Cancer

Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment

Stacy Loeb [a,*], *Yasin Folkvaljon* [b], *David Robinson* [c], *Thorsten Schlomm* [d], *Hans Garmo* [e], *Pär Stattin* [c,f]

[a] *Department of Urology, Population Health, and Laura & Isaac Perlmutter Cancer Center, New York University, NY, USA;* [b] *Registers and Care Programs, Uppsala University Hospital, Uppsala, Sweden;* [c] *Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden;* [d] *Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;* [e] *Division of Cancer Studies, Cancer Epidemiology Unit, King's College London, London, UK;* [f] *Department of Urology, Uppsala University Hospital, Uppsala, Sweden*

Article info

Article history:
Accepted December 11, 2015

Associate Editor:
Giacomo Novara

Keywords:
Phosphodiesterase inhibitors
Viagra
Erectile dysfunction
Prostate cancer
Recurrence

Abstract

Background: Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer (BCR) after radical prostatectomy.
Objective: To evaluate the association between PDE5i use and BCR after radical prostatectomy and radiation therapy in a nationwide population-based cohort.
Design, setting, and participants: This was a nested case-control study using the National Prostate Cancer Register of Sweden linked to the Prescribed Drug Register. Among men with localized prostate cancer who underwent primary radical prostatectomy or radiation therapy during 2006–2007 with 5 yr of follow-up, 293 had BCR after treatment (cases). For each case we identified 20 BCR-free controls (n = 5767) using incidence density sampling.
Outcome measurements and statistical analysis: Multivariable conditional logistic regression was used to examine the association between PDE5i use and BCR risk. Separate multivariable models including clinical variables for men undergoing prostatectomy or radiotherapy and including surgical pathology after prostatectomy were also analyzed.
Results and limitations: PDE5i use was not associated with BCR after radical prostatectomy (odds ratio [OR] 0.78, 95% confidence interval [CI] 0.59–1.03) or radiation therapy (OR 0.98, 95% CI 0.49–1.97) after adjusting for marital status, education, income, prostate-specific antigen, clinical stage, Gleason score, and proportion of positive biopsies. Results were similar after additional adjustment for surgical pathology (OR 0.86, 95% CI 0.64–1.16). Men whose cumulative number of PDE5i pills was above the median had a slightly lower BCR risk after prostatectomy in the clinical model, and no difference in BCR risk after adjustment for pathologic tumor features.
Conclusions: Our results from a population-based cohort suggest that BCR risk is not higher among men using PDE5i after prostate cancer treatment.
Patient summary: Erectile dysfunction medications are not associated with a higher risk of disease recurrence after prostate cancer treatment.

* Corresponding author. Department of Urology, Population Health, and Laura & Isaac Perlmutter Cancer Center, New York University, 550 1st Avenue, New York, NY 10016, USA. Tel. +1 646 8256358; Fax: +1 212 2634549.
E-mail address: stacyloeb@gmail.com (S. Loeb).

http://dx.doi.org/10.1016/j.eururo.2015.12.013
0302-2838/

1. Introduction

Phosphodiesterase type 5 inhibitors (PDE5i) are recommended as first-line therapy for erectile dysfunction following prostate cancer (PCa) treatment [1]. On the basis of laboratory studies suggesting possible antineoplastic effects of PDE5i, Michl et al [2] examined whether PDE5i were associated with a reduction in the risk of PCa progression after radical prostatectomy. Among 4752 surgical patients from a tertiary referral center in Germany, there was a significantly lower progression-free survival rate among postoperative PDE5i users after multivariable adjustment [2]. A follow-up study by Gallina et al [3] including 2579 cases from a tertiary referral center in Italy found no difference in the 5-yr progression-free survival rate according to the number of PDE5i pills used postoperatively.

Given the frequency with which PDE5i medications are used, an association with PCa oncologic outcomes would have important consequences. The aim of the current study was to evaluate the relationship between PDE5i use and PCa biochemical recurrence (BCR) using data from the population-based National Prostate Cancer Register (NPCR) and The Prescribed Drug Register of Sweden.

2. Patients and methods

The NPCR of Sweden includes 98% of prostate cancer cases nationwide, with detailed data on tumor characteristics and primary treatment. In the Prostate Cancer Data Base (PCBaSe), the NPCR is cross-linked to other health care registries and demographic databases [4]. Since 2005 this has included the Prescribed Drug Register, with data on all filled prescriptions in Sweden.

For cases diagnosed during 2003–2007, the NPCR performed a follow-up study of men aged ≤70 yr diagnosed with localized PCa (serum prostate-specific antigen [PSA] <20 ng/ml, clinical stages T1/T2). Since the Prescribed Drug Register started in July 2005, we limited the current study to men in the follow-up study treated by radical prostatectomy or radiation therapy from 2006–2007.

Within this population, we identified 293 men with BCR after treatment, defined as two PSA measurements ≥0.2 ng/ml for men undergoing radical prostatectomy and two PSA measurements ≥2 ng/ml over the nadir for radiation therapy, with the date of the first such measurement considered the date of BCR. For each of these cases, we identified 20 controls who were BCR-free at the event date for the index case using incidence density sampling stratified by age at diagnosis and treatment type ($n = 5767$ controls). A man who had previously been selected as a control remained as a control in this case-control set even if he became a case at a later time point. To account for differences in exposure time between cases and controls, sensitivity analyses were performed with stratification according to exposure time.

The Prescribed Drug Register was used to identify filled prescriptions for sildenafil, vardenafil, and tadalafil after PCa treatment. We examined overall PDE5i use, as well as cumulative counts of the number of filled pills.

Demographic data and tumor features were compared between cases and controls using the t test and χ^2 test. Multivariable conditional logistic regression was used to examine the relationship between overall PDE5i use and cumulative number of pills and BCR. For men undergoing radical prostatectomy and radiation therapy, we assessed clinical models adjusted for the following covariates: marital status (married vs not currently married), educational level (low, middle, high), income (per quartile), PSA (continuous in 1-ng/ml increments), clinical local stage (T2 vs ≤T1c), biopsy Gleason grade group [5] (increasing GGG 1, 2, 3, and combined 4–5 owing to low numbers), and proportion of positive biopsies (>33% vs ≤33%). Information on the level of education was obtained from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) socioeconomic database, and was categorized as low (<10 yr, mandatory school), intermediate (10–12 yr, high school) or high (>12 yr, university or equivalent). For men undergoing radical prostatectomy, we also performed separate multivariable models adjusted for pathologic stage (non–organ-confined vs organ-confined), prostatectomy Gleason grade group (increasing GGG 1, 2, 3, and 4–5), and surgical margin status (negative, positive, indeterminate). Multivariable models were also assessed after additional adjustment for adjuvant therapy, defined as use of androgen deprivation therapy within 1 yr or radiation therapy within 6 mo after radical prostatectomy.

R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses. The study was approved by the Research Ethics Board of Umeå University Hospital.

3. Results

The study population consisted of 293 men with BCR after PCa treatment and 5767 BCR-free controls, of whom 150 (51%) and 3334 (58%), respectively, used PDE5i pills after treatment. Table 1 shows demographic data for the study population stratified by treatment received, and Supplementary Table 1 shows cumulative pill counts for each PDE5i.

Table 2 shows multivariable conditional logistic regression models for BCR including clinical features and PDE5i use. PDE5i use was not associated with BCR in men who underwent radical prostatectomy (odds ratio [OR] 0.78, 95% confidence interval [CI] 0.59–1.03) or radiation therapy (OR 0.98, 95% CI 0.49–1.97). Higher PSA and biopsy GGG were significant predictors of BCR after prostatectomy and radiation therapy. Clinical stage and >33% positive biopsy cores were also significant predictors of BCR after prostatectomy. In separate models additionally adjusted for pathology features (Supplementary Table 2), there was no significant association between PDE5i use and BCR. Non–organ-confined disease, increasing GGG, and positive or indeterminate surgical margins were significant predictors of BCR. The results were similar after additional adjustment for use of adjuvant therapy. On stratification by exposure time, there was no association between PDE5i exposure and BCR risk.

Finally, we examined whether a greater cumulative number of PDE5i pills was associated with the BCR risk after radical prostatectomy (Table 3). Men whose cumulative number of PDE5i pills was above the median had a slightly lower BCR risk in the clinical model (OR 0.68, 95% CI 0.48–0.96), and no difference in BCR risk after adjustment for prostatectomy features (OR 0.73, 95% CI 0.51–1.04).

4. Discussion

In this nested case-control study using a large nationwide, population-based registry, we found no significant relationship between PDE5i use with PCa recurrence after treatment. In fact, a greater number of cumulative PDE5i pills after treatment was associated with a slightly lower

Please cite this article in press as: Loeb S, et al. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. Eur Urol (2015), http://dx.doi.org/10.1016/j.eururo.2015.12.013